Summary – Week 47 (ending 24 November 2019)

- During week 47, influenza activity has continued to increase for several indicators.
- The impact of flu on healthcare services is at moderate intensity levels for hospitalisations and Below baseline for ICU/HDU influenza admissions.
- Respiratory Syncytial Virus (RSV) continues to circulate in the <5 year olds in England.

**Community**
- 190 new acute respiratory outbreaks have been reported in the past 7 days compared to 122 in the previous week. 34 outbreaks were reported from care homes where 6 tested positive for influenza A(unknown subtype). Four outbreaks were reported from hospitals where 1 tested positive for influenza A(unknown subtype) and 1 mixed respiratory infection. 142 outbreaks were reported from schools where 9 tested positive for influenza A(unknown subtype) and 1 for influenza B. The remaining 10 outbreaks were from the Other settings category.

**Primary Care**
- The rate of influenza-like illness (ILI) was Below baseline threshold levels. The overall weekly ILI GP consultation rate was 6.5 per 100,000 registered population in participating GP practices for England, an increase from 5.3 per 100,000 in the previous week.
- In the devolved administrations, ILI rates were Below baseline threshold levels for Northern Ireland, Scotland and Wales.

**Secondary Care**
- Hospitalisation rate observed for laboratory confirmed influenza was at moderate intensity levels, with a rate of 2.80 per 100,000 trust catchment population for England (21 NHS Trusts) compared to 1.38 per 100,000 in the previous week.
- ICU/HDU admission rate observed for laboratory confirmed influenza was Below baseline levels, with a rate of 0.08 per 100,000 trust catchment population for England (133/143 NHS Trusts) compared to 0.05 per 100,000 the previous week.
- There was one laboratory confirmed influenza admission (1 influenza A(unknown subtype)) reported from the 6 Severe Respiratory Failure centres in the UK.

**All-cause mortality**
- In week 47 2019, no statistically significant excess all-cause mortality by week of death was seen overall and by age group in England. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales in week 47 and for Scotland in week 45 2019. No data was available for Northern Ireland in week 47.

**Microbiological surveillance**
- Primary care: 51 samples tested positive for influenza (1 influenza A(H1N1)pdm09, 41 influenza A(H3), 7 influenza A(unknown subtype), 1 influenza B, and one co-infection influenza A(unknown subtype) and B), through the UK GP sentinel swabbing schemes in week 47 2019, with an overall positivity of 31.5%.
- Secondary care: There were 328 detections recorded through the DataMart scheme (11 influenza A(H1N1)pdm09, 193 influenza A(H3), 116 influenza A(not subtyped) and 8 influenza B). The overall influenza percent positivity was 14.5% and Above baseline threshold level.
- Virus Characterisation: 60 influenza A(H3N2) viruses have been genetically and/or antigenically characterised since week 40. 31 of 47 genetically characterised belong to the same subclade as the H3N2 component in this season’s vaccine. Five A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A(H1N1)pdm09 strain in this season’s vaccine.

**Vaccination**
- Weekly uptake: Up to week 47 2019, in 93.9% of GP practices reporting for the main collection, the provisional proportion of people in England who had received the 2019/20 influenza vaccine in targeted groups was: 33.0% in under 65 years in a clinical risk group, 35.5% in pregnant women and 66.1% in 65+ year olds. In 93.2% of GP practices reporting for the childhood collection, the provisional proportion vaccinated was: 21.1% in 2 year olds and 20.4% in 3 year olds.
- Provisional data from the first monthly collection of influenza vaccine uptake by frontline healthcare workers show 43.6% were vaccinated by 31 October 2019, compared to 46.3% vaccinated in the previous season by 31 October 2018.
- Provisional data from the first monthly collection of influenza vaccine uptake for children of school years reception to year 6 shows 17.9% in school year reception age, 17.6% in school year 1 age, 17.3% in school year 2 age, 16.6% in school year 3 age, 16.4% in school year 4 age, 15.8% in school year 5 and 15.2% in school year 6 age were vaccinated by 31 October 2019.

**International situation**
- In the temperate zone of the northern hemisphere, influenza activity remained at inter-seasonal levels in most countries; however continued to increase across the countries of the Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to inter-seasonal levels in most countries and decreased to low levels in Chile. Worldwide, seasonal influenza A accounted for the majority of detections, with equal proportions of influenza A(H1N1)pdm09 and A(H3N2) viruses.
190 new acute respiratory outbreaks were reported in the past 7 days, with 16 confirmed with influenza. ILI rates observed through internet based surveillance increased and breached the baseline threshold for the FluDetector system.

- Acute respiratory disease outbreaks
  - 190 new acute respiratory outbreaks have been reported in the past 7 days. 34 outbreaks were reported from care homes where 6 tested positive for influenza A (unknown subtype) and 4 tested positive for rhinovirus and 2 for RSV. Four outbreaks were reported from a hospital where one tested positive for influenza A (unknown subtype) and one mixed respiratory infection. 142 outbreaks were reported from schools where 9 tested positive for influenza A (unknown subtype), one was positive for influenza B and one for RSV. The remaining 10 outbreaks were from the Other settings category where one tested positive for RSV. Of the 190 outbreaks 60 were reported from the North East region and 46 were reported from the North West region.

-Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and respdcidsc@phe.gov.uk

- Medical Officers of Schools Association (MOSA) & PHE surveillance scheme
  - Boarding schools in England within the MOSA network are recruited each season to report various respiratory related illnesses including influenza like illnesses (ILI). For the 2019/20 season, 17 MOSA schools have agreed to participate in the scheme, including a total of 4,000 boarders.
  - The overall rate (all boarders) for week 47 was 0.4 per 1,000 boarders compared to 0.6 per 1,000 boarders in the previous week.
  - If you are a MOSA school and would like to participate in this scheme, please email mosa@phe.gov.uk for more information.

- FluSurvey
  - Internet-based surveillance of influenza-like illness in the general population is undertaken through FluSurvey. A project run by PHE to monitor ILI activity in the community.
  - The overall ILI rate (all age groups) for week 47 was 25.1 per 1,000 (47/1,875 people reported at least 1 ILI) compared to 46.0 per 1,000 in week 46, with the highest rate seen in the <20 year olds (64.9 per 1,000).
  - If you would like to become a participant of the FluSurvey project please do so by visiting the https://flusurvey.net/en/accounts/register/ website for more information.

- FluDetector
  - Internet-based surveillance of influenza-like illness in the general population is also undertaken through FluDetector (https://fludetector.cs.ucl.ac.uk), a model assessing internet-based search queries for ILI.
  - Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the six days before it).
  - The daily ILI rate estimates for week 47 continued to increase crossing the baseline threshold of 11.7 per 100,000, with an overall weekly rate of 13.7 per 100,000 compared to 9.3 per 100,000 in week 46 (Figure 2).
  - For more information on i-sense and the work carried out on early warning sensing systems for infectious disease visit https://www.i-sense.org.uk/
In week 47, the overall weekly influenza-like illness (ILI) GP consultation rate remained below baseline threshold levels in England. In the devolved administrations, ILI rates were below their respective baselines.

- **GP ILI consultations in the UK**

  **RCGP (England)**

  - The weekly ILI consultation rate through the RCGP surveillance was 6.5 per 100,000 registered population in participating GP practices in week 47 compared to 5.3 per 100,000 in week 46. This is below the baseline threshold (12.7 per 100,000) (Figure 3*). By age group, the highest rates were seen in the 5-14 year olds (9.0 per 100,000) and in the 1-4 year olds (8.8 per 100,000).

  *The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10) in a standardised approach across Europe. For MEM intensity threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

  **UK**

  - In week 47, overall weekly ILI consultation rates across the countries of the UK were all below their respective baseline threshold levels (Table 1).
  - By age group, the highest rates were seen in the 15-44 year olds in Scotland (16.0 per 100,000) and in the 5-14 year olds in Northern Ireland and Wales (22.4 and 13.6 per 100,000, respectively).

  **Table 1: GP ILI consultations in the UK for all ages with MEM thresholds applied***

<table>
<thead>
<tr>
<th>GP ILI consultation rates (all ages)</th>
<th>Week number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>40</td>
</tr>
<tr>
<td>England (RCGP)</td>
<td>4.3</td>
</tr>
<tr>
<td>Wales</td>
<td>1.7</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>3.0</td>
</tr>
</tbody>
</table>

  *The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity (based on 10 seasons excluding 2009/10), in a standardised approach across Europe. For MEM threshold values for each country, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#clinical-surveillance-through-primary-care

- **GP In Hours Syndromic Surveillance System (England)**

  The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is 6.4 per 100,000 in week 47 2019 (Figure 4).

  GP In Hours consultations for ILI remain below baseline levels, however consultations increased just above baseline in North East, North West, and Yorkshire and Humber for week 47. The greatest increase in ILI have been noted in the 5-14 year age group.

  NHS 111 cold/flu calls increased above baseline threshold with increases particularly noted in 5-14 year olds. There were further increases in both cough and difficulty breathing calls in children aged under 15 years, in line with seasonal RSV activity during week 47.

  GP Out of Hours consultations and Emergency Department (ED) attendances for ILI increased during week 47. Further increases were also observed for bronchitis/bronchiolitis, particularly in young children(aged under 1 year), in line with increasing levels of RSV activity in week 47.

  - Figure 4 represents a map of GP ILI consultation rates in week 47 across England by PHE centres, with ILI surveillance MEM thresholds applied.

  ILI thresholds were calculated separately for each of the nine PHE Centres to allow for differences between areas e.g. background ILI rates are historically higher in London than other areas of England and based upon previous influenza seasons from 2012/13 on wards. ILI thresholds should be interpreted with caution and reference made to other GP surveillance systems incorporating more historical data.
In week 47 2019, there were 261 hospitalised confirmed influenza cases (7 influenza A(H1N1)pdm09, 146 influenza A(H3N2), 104 influenza A(unknown subtype) and 4 influenza B) reported through the USISS sentinel hospital network across England (21 Trusts). There were 43 new admissions to ICU/HDU with confirmed influenza (12 influenza A(H3N2), 28 influenza A(unknown subtype) and 3 influenza B) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (133/143 Trusts in England).

- USISS sentinel weekly hospitalised confirmed influenza cases, England (week 47)

In week 47, there were 261 hospitalised laboratory confirmed influenza cases (7 influenza A(H1N1)pdm09, 146 influenza A(H3N2), 104 influenza A(unknown subtype) and 4 influenza B) reported from 21 NHS Trusts across England through the USISS sentinel hospital network, with a rate of 2.80 per 100,000 trust catchment population (Figures 5 and 6) compared to 1.38 per 100,000 in week 46. This is above the low impact threshold of 2.65 per 100,000.

A total of 605 hospitalised confirmed influenza admissions (17 influenza A(H1N1)pdm09, 316 influenza A(H3N2), 255 influenza A(unknown subtype) and 17 influenza B) have been reported in England since week 40 2019 via the sentinel scheme.

- Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 47)

In week 47, there were 43 new admissions to ICU/HDU with confirmed influenza (12 influenza A(H3N2), 28 influenza A(unknown subtype) and 3 influenza B) reported across the UK (133/143 Trusts in England) through the USISS mandatory ICU scheme, with a rate of 0.08 per 100,000 (Figures 7 and 8) compared to 0.05 per 100,000 in week 46. This is below the baseline impact threshold of 0.10 per 100,000. Two influenza laboratory confirmed deaths were reported to have occurred in ICU/HDU week 47 in the UK.

A total of 125 new admissions (8 influenza A(H1N1)pdm09), 19 influenza A(H3N2), 89 influenza A(unknown subtype) and 9 influenza B) and 3 confirmed deaths have been reported in the UK since week 40 2019.

*The Moving Epidemic Method (MEM) has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for ICU/HDU admission rates for the start of influenza activity (based on 7 seasons) in a standardised approach across Europe. For MEM threshold values, please visit: https://www.gov.uk/guidance/sources-of-uk-flu-data-influenza-surveillance-in-the-uk#disease-severity-and-mortality-data*
In week 47 2019, no statistically significant excess all-cause mortality by week of death was observed overall and by age group in England, through the EuroMOMO algorithm. In the devolved administrations, no statistically significant excess all-cause mortality for all ages was observed in Wales in week 47 2019 and for Scotland in week 45.

- All-cause death registrations, England and Wales
  - In week 46 2019, an estimated 10,650 all-cause deaths were registered in England and Wales (source: Office for National Statistics). This is a slight decrease compared to the 10,697 estimated death registrations in week 45 2019.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland
  - In week 47 2019 in England, no statistically significant excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group and sub-nationally (all ages), after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm. This data is provisional due to the time delay in registration; numbers may vary from week to week.

  - In the devolved administrations, no statistically significant excess all-cause mortality for all ages observed in Wales in week 47 2019 and for Scotland in week 45 (Table 2). Data was unavailable for Northern Ireland in week 47.

**All-cause mortality data**

**Table 2: Excess mortality by UK country, for all ages**

* Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold
* NA refers to no excess seen

<table>
<thead>
<tr>
<th>Country</th>
<th>Excess detected in week 47 2019?</th>
<th>Weeks with excess in 2019/20</th>
</tr>
</thead>
<tbody>
<tr>
<td>England</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Wales</td>
<td>×</td>
<td>NA</td>
</tr>
<tr>
<td>Northern Ireland</td>
<td>-</td>
<td>NA</td>
</tr>
<tr>
<td>Scotland</td>
<td>×</td>
<td>41</td>
</tr>
</tbody>
</table>

Figure 9: Weekly observed and expected number of all-age all-cause deaths, with the dominant circulating influenza A subtype, England, 2015 to week 47 2019

*Note: Delays in receiving all registered deaths from April 2018, following changes in IT systems at ONS, may result in some delays in the model to adjust for most recent deaths.
In week 47 2019, 51 samples tested positive for influenza with an overall positivity of 31.5%, through the UK GP sentinel schemes. 328 positive detections were recorded through the DataMart scheme (11 influenza A(H1N1)pdm09, 193 influenza A(H3), 116 influenza A(not subtyped) and 8 influenza B) with a positivity of 14.5%, this is above the baseline threshold of 9.7%.

- Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations
- Respiratory DataMart System (England)

Since week 40, a total of 145 samples (11 influenza A(H1N1)pdm09, 107 influenza A(H3N2), 15 influenza A(unknown subtype), 6 influenza B, two co-infections of influenza A(H3N2) and B, two co-infections of influenza A(H1N1)pdm09 and B, one co-infection of influenza A(H1N1)pdm09 and influenza A(H3) and one co-infection of influenza A(unknown subtype) and B) tested positive for influenza through this scheme.

RSV positivity continued to increase from 8.5% in week 46 to 9.5% in week 47. The highest positivity for RSV by age group was seen in the <5 year olds at 32.8% in week 47 compared to 30.0% in the previous week. Rhinovirus and parainfluenza positivity decreased to 13.6% and 4.1% respectively in week 47. Adenovirus and human metapneumovirus (hMPV) positivity were low at 2.5% and 1.8% respectively in week 47 2019 (Figure 13).

*The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive is calculated through the Moving Epidemic Method is 9.7% in 2019/20.*
Virus characterisation

PHE characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

The PHE Respiratory Virus Unit has characterised 60 influenza A(H3N2) viruses detected since week 40. 60 influenza A (H3N2) viruses have been genetically and/or antigenically characterised. Of the 47 influenza A (H3N2) viruses genetically characterised, 31 belong to the genetic clade 3C.3a, and 16 fall into a cluster within the 3C.2a1 subclade, designated 3C.2a1b. All of the 35 A(H3N2) viruses antigenically characterised are similar to the A/Kansas/14/2017-like Northern Hemisphere 2019/20 (H3N2) vaccine strain. The Northern Hemisphere 2019/20 influenza A(H3N2) vaccine strain belongs in genetic subclade 3C.3a. Thirty-five A(H3N2) viruses have been antigenically characterised and are similar to the A/Kansas/14/2017-like Northern Hemisphere 2019/20 (H3N2) vaccine strain. Difficulties remain with detection and typing of A(H3N2) viruses by HI assays due to observed receptor binding changes, particularly with viruses from the 3C.2a1 subclade and these are under-represented in the antigenic characterisation data.

A total of seven A(H1N1)pdm09 viruses have been characterised to date. Four A(H1N1)pdm09 viruses have been genetically characterised, all fall in clade 6B.1A which was the predominant genetic clade in the 2018/19 season. Five A(H1N1)pdm09 viruses have been antigenically characterised and are similar to the A/Brisbane/02/2018-like N. Hemisphere 2019/20 A(H1N1)pdm09 vaccine strain.

One influenza B virus has been characterised to date, where sequencing of the haemagglutinin (HA) gene shows this virus belongs in genetic clade 1A of the B/Victoria lineage, clustering in a subgroup within this clade characterised by deletion of three amino acids in the HA. The N. Hemisphere 2019/20 B/Victoria-lineage quadrivalent and trivalent vaccine component virus (a B/Colorado/06/2017-like virus) belongs in genetic clade 1A, clustering in a subgroup with two deletions in the HA.

At this early stage of the influenza season, it is too early to predict which lineages will dominate throughout the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.

Table 3: Viruses characterised by PHE Reference Laboratory, 2019/20

<table>
<thead>
<tr>
<th>Virus type/subtype</th>
<th>Genetic and antigenic</th>
<th>Genetic only</th>
<th>Antigenic only</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H1N1)pdm09</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>A(H3N2) 3C.2a1</td>
<td>0</td>
<td>16</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>A(H3N2) 3C.3a</td>
<td>22</td>
<td>9</td>
<td>13</td>
<td>44</td>
</tr>
<tr>
<td>A(H3N2) total</td>
<td>22</td>
<td>25</td>
<td>13</td>
<td>60</td>
</tr>
<tr>
<td>B/Yamagata-lineage</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

Antiviral susceptibility

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

Since week 40 2019, eight influenza A (H1N1) viruses and 28 influenza A (H3N2) viruses were tested for both antiviral agents, oseltamivir and zanamivir, and all viruses are sensitive.

Antimicrobial susceptibility

- Table 4 shows in the 12 weeks up to 24 November 2019, the proportion of all lower respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community-acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Antibiotic</th>
<th>Specimens tested (%)</th>
<th>Specimens susceptible (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. pneumoniae</td>
<td>Penicillin</td>
<td>3277</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>3569</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>3518</td>
<td>82</td>
</tr>
<tr>
<td>H. influenzae</td>
<td>Amoxicillin/ampicillin</td>
<td>12712</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td>Co-amoxiclav</td>
<td>14157</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>2415</td>
<td>82</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>14173</td>
<td>82</td>
</tr>
<tr>
<td>S. aureus</td>
<td>Methicillin</td>
<td>6823</td>
<td>92</td>
</tr>
<tr>
<td></td>
<td>Macrolides</td>
<td>7653</td>
<td>66</td>
</tr>
<tr>
<td>MRSA</td>
<td>Clindamycin</td>
<td>382</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>580</td>
<td>78</td>
</tr>
<tr>
<td>MSSA</td>
<td>Clindamycin</td>
<td>4496</td>
<td>72</td>
</tr>
<tr>
<td></td>
<td>Tetracycline</td>
<td>5939</td>
<td>92</td>
</tr>
</tbody>
</table>

*Macrolides = erythromycin, azithromycin and clarithromycin
• Up to week 47 2019 in 93.9% of GP practices reporting weekly to Immform for the main collection, the provisional proportion of people in England who had received the 2019/20 influenza vaccine in targeted groups was as follows (Figure 14):
  - 33.0% in under 65 years in a clinical risk group
  - 35.5% in pregnant women
  - 66.1% in 65+ year olds

![Figure 14: Cumulative weekly influenza vaccine uptake by target group in England](image1)

- In 2019/20, all 2 and 3 year olds continue to be eligible for influenza vaccination through their GPs. Up to week 47 2019, in 93.2% of GP practices reporting weekly to Immform for the childhood collection, the provisional proportion of children in England who had received the 2019/20 influenza vaccine in targeted groups was as follows (Figure 15):
  - 21.1% in 2 year olds
  - 20.4% in 3 year olds

![Figure 15: Cumulative weekly influenza vaccine uptake by target group in England](image2)

- Provisional data from the first monthly collection of the influenza vaccine uptake by frontline healthcare workers show 43.6% were vaccinated by 31 October 2019 from 96.6% of all organisations, compared to 46.3% vaccinated in the previous season by 31 October 2018. The report provides uptake at national, NHS England local team and Trust-level.
Provisional data from the first monthly collection of influenza vaccine uptake for children of school years Reception, 1, 2, 3, 4, 5 and 6 age (from a sample of 100% of all Local Authorities in England) show the provisional proportion of children in England who received the 2019/20 influenza vaccine via school, pharmacy or GP practice by 31 October 2019 in targeted groups in Table 5.

Table 5: Provisional cumulative influenza vaccine uptake (%) in children in school years Reception to Year 6, up to 31 October 2019 & 2018, England

<table>
<thead>
<tr>
<th>School Year</th>
<th>% Vaccine uptake (up to 31 October)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2019/20</td>
</tr>
<tr>
<td>Reception (4-5 years)</td>
<td>17.9</td>
</tr>
<tr>
<td>Year 1 (5-6 years)</td>
<td>17.6</td>
</tr>
<tr>
<td>Year 2 (6-7 years)</td>
<td>17.3</td>
</tr>
<tr>
<td>Year 3 (7-8 years)</td>
<td>16.6</td>
</tr>
<tr>
<td>Year 4 (8-9 years)</td>
<td>16.4</td>
</tr>
<tr>
<td>Year 5 (9-10 years)</td>
<td>15.8</td>
</tr>
<tr>
<td>Year 6 (10-11 years)</td>
<td>15.2</td>
</tr>
</tbody>
</table>

- : Year 6 were not part of the programme in 2018/19

International Situation

In the temperate zone of the northern hemisphere, influenza activity remained at inter-seasonal levels in most countries; however continued to increase across the countries of the Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to interseasonal levels in most countries and decreased to low levels in Chile. Worldwide, seasonal influenza A accounted for the majority of detections, with equal proportions of influenza A(H1N1)pdm09 and A(H3N2) viruses.

- Europe updated on 22 November 2019 (Joint ECDC-WHO Europe Influenza weekly update)

Overall in week 46, influenza activity was low throughout the European Region and mixed circulation of influenza A and B viruses was detected. There are early signs of influenza B dominance in some central Asian countries.

For week 46 2019, of 47 Member States and areas reporting on intensity, 43 reported baseline and 4 reported low intensity (across the Region). Of the same Member States reporting on geographic spread, 23 reported no activity, 20 reported sporadic cases and three reported local spread.

For week 46 2019, 60 (6.6%) of 910 sentinel specimens tested positive for an influenza virus; 36 were influenza type A (11 A(H1N1)pdm09, 18 A(H3N2) and 7 influenza A(unknown subtype)), and 11 was influenza type B (all B/Victoria).

For the season overall, more influenza type A (n=143, 61.6%) than type B (n=89, 38.4%) viruses have been detected. Of 135 subtyped A viruses, 51 (37.8%) were A(H1N1)pdm09 and 84 (62.2%) were A(H3N2). Of 25 influenza type B viruses ascribed to a lineage, 24 (96%) were B/Victoria and 1 (4%) B/Yamagata.

Since week 40/2019, 86 laboratory-confirmed influenza cases from ICUs have been reported. 80 were infected with influenza type A and 6 with influenza type B. Of 16 subtyped influenza A viruses, 8 were A(H1N1)pdm09 and 8 A(H3N2). None of the influenza B viruses were ascribed to a lineage.

Since week 40/2019, 47 laboratory-confirmed influenza cases from other wards have been reported; of these 43 were infected by influenza type A viruses, with 30 subtyped as A(H3N2), and 4 by influenza type B viruses.

For week 46 2019, pooled estimates from the EuroMOMO project of all-cause mortality from 22 countries or areas show mortality levels are within normal expected ranges.

- United States of America updated on 22 November 2019 (Centre for Disease Control report)

During week 46, influenza activity continues to increase in the United States and the predominant influenza virus varies by region.

Nationwide during week 46, 2.5% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI), which is above the national baseline of 2.4% for the first time.
During week 46, 7.3% of respiratory specimens tested by clinical laboratories were influenza positive. This is higher than the previous week.

Based on National Center for Health Statistics (NCHS) mortality surveillance data available on November 21, 2019, 5.2% of the deaths occurring during the week ending November 9, 2019 (week 45) were due to P&I. This percentage is below the epidemic threshold of 6.2% for week 45.

- **Canada** updated on 22 November 2019 (Public Health Agency report)

At national level, influenza activity continues to increase but remains below the seasonal threshold at the national level in week 46, with influenza A(H3N2) continuing to be the most common influenza virus circulating in Canada.

In weeks 46, a total of 223 laboratory detections of influenza were reported, of which 68% (152) were influenza A, with 34/56 subtyped influenza A detections being influenza A(H3N2).

The percentage of tests positive for influenza increased but remains at interseasonal levels, at 4.1% in week 46.

In week 46, 1.5% of visits to healthcare professionals were due to ILI, respectively.

To date this season, 77 influenza-associated hospitalisations have been reported with the majority of cases being aged greater than 65 years and associated with influenza A(H3N2).

- **Global influenza update** updated on 25 November 2019 (based on data up to 10 November 2019) (WHO website)

In the temperate zone of the northern hemisphere, influenza activity remained at inter-seasonal levels in most countries; however continued to increase across the countries of the Western Asia. In the temperate zones of the southern hemisphere, influenza activity returned to interseasonal levels in most countries and decreased to low levels in Chile. Worldwide, seasonal influenza A accounted for the majority of detections, with equal proportions of influenza A(H1N1)pdm09 and A(H3N2) viruses.

Respiratory illness indicators started to increase in some countries of the WHO European region, Eastern Asia and in North America, but influenza detections remain below seasonal thresholds.

In Western Asia, influenza activity continued to increase overall. Bahrain and Saudi Arabia reported predominant detection of influenza A(H1N1)pdm09 and a small proportion of B viruses. Kuwait and Oman reported detections of all seasonal influenza subtypes co-circulating and Qatar reported predominant circulation of influenza A(H3N2) viruses.

In the Caribbean countries and tropical countries of South America, influenza activity remained low overall, however increased detections of influenza A(H3N2) and B/Victoria lineage were reported in Cuba.

In Central American countries, decreased influenza activity was reported in El Salvador and Nicaragua, with influenza A(H1N1)pdm09 and B/Victoria co-circulating in the former and A(H3N2) and B viruses co-circulating in the latter.

In Western Africa, influenza activity was elevated in some reporting countries. Increased influenza virus detections with predominantly influenza A(H3N2) and B/Victoria lineage viruses continued to be reported in Côte d’Ivoire, Ghana, and Guinea and influenza A(H3N2) in Niger. Increased influenza activity due to influenza A(H3N2) and B viruses was reported in Togo.

In Middle Africa, influenza detections of all seasonal influenza subtypes were reported in Cameroon and a few detections of influenza B/Victoria lineage viruses were reported in South Sudan.

In Eastern Africa, influenza detections were low across most reporting countries.

In Southern Asia, influenza detections were low across reporting countries except for Iran (Islamic Republic of) where influenza activity continued to increase with detections of predominantly influenza A(H1N1)pdm09 viruses.

In South East Asia, influenza activity was reported in some countries. Influenza activity remained elevated in Lao PDR, with detections of predominately influenza B/Victoria-lineage and influenza A(H3N2) viruses. Influenza virus detections of predominantly influenza A viruses continued to be reported at low level in Cambodia and Thailand.
The WHO GISRS laboratories tested more than 85,126 specimens between 28 October 2019 and 10 November 2019. 6,187 were positive for influenza viruses, of which 4,608 (74.5%) were typed as influenza A and 1,579 (25.5%) as influenza B. Of the sub-typed influenza A viruses, 1,473 (47.0%) were influenza A (H1N1)pdm09 and 1,664 (53.0%) were influenza A (H3N2). Of the characterized B viruses, 43 (6.2%) belonged to the B-Yamagata lineage and 650 (93.8%) to the B-Victoria lineage.

- **Avian Influenza** latest update on 27 September 2019 (WHO website)

**Influenza A(H5) viruses**
Between 25 June 2019 to 27 September 2019, one new laboratory-confirmed human case of influenza A(H5N6) virus infection was reported to WHO.

A total of 24 laboratory-confirmed cases of human infection with influenza A(H5N6) virus have been reported to WHO from China since 2014.

According to reports received by the World Organization for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in Africa, Europe and Asia.

**Influenza A(H7N9)**
Between 25 June 2019 and 27 September 2019, no new laboratory-confirmed human case of influenza A(H7N9) virus infection were reported to WHO from China. Publicly available reports from animal health authorities in China of influenza A(H7N9) virus detections in animals in recent months indicate virus detections in two provinces from samples taken in the first half of the year. Overall, the risk assessment has not changed.

For more information on A(H5), A(H7N9), A(H9N2) and A(H1)\(v\) viruses, please see the September 2019 report: *Antigenic and genetic characteristics of zoonotic influenza viruses and candidate vaccine viruses developed for potential use in human vaccines*.

- **Middle East respiratory syndrome coronavirus (MERS-CoV)** latest update on 26 November 2019

Up to 26 November 2019, a total of five cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (three imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 1,714 suspected cases in the UK since September 2012 that have been investigated for MERS-CoV and tested negative.

On 7 October 2019, the National IHR Focal Point of the United Arab Emirates (UAE) notified WHO of one laboratory-confirmed case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

Between 1 and 30 September 2019, the National IHR Focal Point of Saudi Arabia reported 4 additional laboratory-confirmed cases of MERS-CoV infection with one associated death.

Globally, since September 2012 and up to 08 October 2019, WHO has been notified of 2,470 laboratory-confirmed cases of infection with MERS-CoV, including 851 related deaths. Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment can be found here, where it is highlighted that risk of widespread transmission of MERS-CoV remains very low.

**Acknowledgements**
This report was prepared by the Influenza section, Immunisations and Countermeasures Division, National Infection Service, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSsurveillance® and EMIS and EMIS practices contributing to the QSsurveillance® database.

**Related links**

**Sources of flu data**
- Clinical surveillance through primary care in the UK
• Outbreak reporting
• FluSurvey
• MOSA
• Real time syndromic surveillance
• MEM threshold methodology paper and UK pilot paper

Disease severity and mortality data
• USISS system
• EuroMOMO mortality project

Vaccination
• Seasonal influenza vaccine programme (Department of Health Book)
• Childhood flu programme information for healthcare practitioners (Public Health England)
• 2019/20 Northern Hemisphere seasonal influenza vaccine recommendations (WHO)